Boehringer Ingelheim Collaborates with The Defeat-NCD Partnership to Tackle the Impacts of Non-Communicable Diseases

 Boehringer Ingelheim Collaborates with The Defeat-NCD Partnership to Tackle the Impacts of Non-Communicable Diseases

Boehringer Ingelheim Collaborates with The Defeat-NCD Partnership to Tackle Impacts of Non-Communicable Diseases

Shots:

  • The Defeat-NCD Partnership and BI partnered to address the access to healthcare issues related to NCDs by helping governments to strengthen national institutions, scaling up community-based health services and expanding the accessible range of medicines and healthcare solutions
  • The focus of the collaboration is to tackle premature death, sickness, disability, and associated social and economic impacts from NCDs in low resources countries
  • BI’s portfolio contains 85% therapies targeting NCD and with its Access to Healthcare strategy, based on the three strategic pillars Availability, Innovative Solutions and Sustainable Models to explore & evaluate a holistic approach for broadening healthcare access in underserved communities and countries

Click here to­ read full press release/ article | Ref: Boehringer Ingelheim | Image: WestFair

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post